Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. / Hakii, H.; Fujiki, H.; Suganuma, M.; Nakayasu, M.; Tahira, T.; Sugimura, T.; Scheuer, P. J.; Christensen, S. B.

In: Journal of Cancer Research and Clinical Oncology, Vol. 111, No. 3, 01.06.1986, p. 177-181.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hakii, H, Fujiki, H, Suganuma, M, Nakayasu, M, Tahira, T, Sugimura, T, Scheuer, PJ & Christensen, SB 1986, 'Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis', Journal of Cancer Research and Clinical Oncology, vol. 111, no. 3, pp. 177-181. https://doi.org/10.1007/BF00389230

APA

Hakii, H., Fujiki, H., Suganuma, M., Nakayasu, M., Tahira, T., Sugimura, T., Scheuer, P. J., & Christensen, S. B. (1986). Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. Journal of Cancer Research and Clinical Oncology, 111(3), 177-181. https://doi.org/10.1007/BF00389230

Vancouver

Hakii H, Fujiki H, Suganuma M, Nakayasu M, Tahira T, Sugimura T et al. Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. Journal of Cancer Research and Clinical Oncology. 1986 Jun 1;111(3):177-181. https://doi.org/10.1007/BF00389230

Author

Hakii, H. ; Fujiki, H. ; Suganuma, M. ; Nakayasu, M. ; Tahira, T. ; Sugimura, T. ; Scheuer, P. J. ; Christensen, S. B. / Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. In: Journal of Cancer Research and Clinical Oncology. 1986 ; Vol. 111, No. 3. pp. 177-181.

Bibtex

@article{b15a4981d13f44cea406fad94d6188e7,
title = "Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis",
abstract = "Thapsigargin, a hexaoxygenated tetraacylated sesquiterpene lactone, induced irritation of mouse ear and histidine decarboxylase (HDC) activity in mouse skin, but it did not induce ornithine decarboxylase in mouse skin or adhesion of human promyelocytic leukemia (HL-60) cells. Although thapsigargin did not give consistent positive results in a short-term screening system for tumor promoters, it was tested in a two-stage carcinogenesis experiment on mouse skin. The potency of thapsigargin to induce HDC in mouse skin was used to determine the dose in this experiment. Application of 10 μg (17 nmol) thapsigargin induced HDC activity of 139 pmol CO2/mg protein per 60 min. Tumors were found in the skin of 53.5% of the mice treated with DMBA plus 5 μg (8.5 nmol) thapsigargin in week 22, in none of those treated with thapsigargin alone by week 30. One tumor appeared in 1 of 15 mice treated with DMBA alone in week 21. Thapsigargin cannot bind to the phorbol ester receptor in the particulate fraction of mouse skin and so is classified as a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter. It is a new tumor promoter differing in many respects from the well-defined TPA type tumor promoters. Several naturally occurring analogues of thapsigargin, such as thapsigargicin and thapsitranstagin, might also be new non-TPA type tumor promoters, because thapsigargicin and thapsitranstagin induced irritation of mouse ear and HDC activity in mouse skin.",
keywords = "HDC, Hexaoxygenated tetraacylated sesquiterpene lactone, Histamine releasing activity, Non-TPA type tumor promoter, Thapsigargin",
author = "H. Hakii and H. Fujiki and M. Suganuma and M. Nakayasu and T. Tahira and T. Sugimura and Scheuer, {P. J.} and Christensen, {S. B.}",
year = "1986",
month = jun,
day = "1",
doi = "10.1007/BF00389230",
language = "English",
volume = "111",
pages = "177--181",
journal = "Zeitschrift fur Krebsforschung",
issn = "0171-5216",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanolphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis

AU - Hakii, H.

AU - Fujiki, H.

AU - Suganuma, M.

AU - Nakayasu, M.

AU - Tahira, T.

AU - Sugimura, T.

AU - Scheuer, P. J.

AU - Christensen, S. B.

PY - 1986/6/1

Y1 - 1986/6/1

N2 - Thapsigargin, a hexaoxygenated tetraacylated sesquiterpene lactone, induced irritation of mouse ear and histidine decarboxylase (HDC) activity in mouse skin, but it did not induce ornithine decarboxylase in mouse skin or adhesion of human promyelocytic leukemia (HL-60) cells. Although thapsigargin did not give consistent positive results in a short-term screening system for tumor promoters, it was tested in a two-stage carcinogenesis experiment on mouse skin. The potency of thapsigargin to induce HDC in mouse skin was used to determine the dose in this experiment. Application of 10 μg (17 nmol) thapsigargin induced HDC activity of 139 pmol CO2/mg protein per 60 min. Tumors were found in the skin of 53.5% of the mice treated with DMBA plus 5 μg (8.5 nmol) thapsigargin in week 22, in none of those treated with thapsigargin alone by week 30. One tumor appeared in 1 of 15 mice treated with DMBA alone in week 21. Thapsigargin cannot bind to the phorbol ester receptor in the particulate fraction of mouse skin and so is classified as a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter. It is a new tumor promoter differing in many respects from the well-defined TPA type tumor promoters. Several naturally occurring analogues of thapsigargin, such as thapsigargicin and thapsitranstagin, might also be new non-TPA type tumor promoters, because thapsigargicin and thapsitranstagin induced irritation of mouse ear and HDC activity in mouse skin.

AB - Thapsigargin, a hexaoxygenated tetraacylated sesquiterpene lactone, induced irritation of mouse ear and histidine decarboxylase (HDC) activity in mouse skin, but it did not induce ornithine decarboxylase in mouse skin or adhesion of human promyelocytic leukemia (HL-60) cells. Although thapsigargin did not give consistent positive results in a short-term screening system for tumor promoters, it was tested in a two-stage carcinogenesis experiment on mouse skin. The potency of thapsigargin to induce HDC in mouse skin was used to determine the dose in this experiment. Application of 10 μg (17 nmol) thapsigargin induced HDC activity of 139 pmol CO2/mg protein per 60 min. Tumors were found in the skin of 53.5% of the mice treated with DMBA plus 5 μg (8.5 nmol) thapsigargin in week 22, in none of those treated with thapsigargin alone by week 30. One tumor appeared in 1 of 15 mice treated with DMBA alone in week 21. Thapsigargin cannot bind to the phorbol ester receptor in the particulate fraction of mouse skin and so is classified as a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter. It is a new tumor promoter differing in many respects from the well-defined TPA type tumor promoters. Several naturally occurring analogues of thapsigargin, such as thapsigargicin and thapsitranstagin, might also be new non-TPA type tumor promoters, because thapsigargicin and thapsitranstagin induced irritation of mouse ear and HDC activity in mouse skin.

KW - HDC

KW - Hexaoxygenated tetraacylated sesquiterpene lactone

KW - Histamine releasing activity

KW - Non-TPA type tumor promoter

KW - Thapsigargin

UR - http://www.scopus.com/inward/record.url?scp=0022578105&partnerID=8YFLogxK

U2 - 10.1007/BF00389230

DO - 10.1007/BF00389230

M3 - Journal article

C2 - 2426275

AN - SCOPUS:0022578105

VL - 111

SP - 177

EP - 181

JO - Zeitschrift fur Krebsforschung

JF - Zeitschrift fur Krebsforschung

SN - 0171-5216

IS - 3

ER -

ID: 232599815